Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Peginterferon Lambda  COVID-19 treatment studies for Peg.. Lambda  C19 studies: Peg.. Lambda  Peg.. Lambda   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
 
    
  
Peginterferon Lambda for COVID-19
3 studies from 63 scientists
2,116 patients in 3 countries
Statistically significant improvement for hospitalization.
2 studies from 2 independent teams in 2 countries show statistically significant improvements in isolation.
COVID-19 Peginterferon Lambda studies. Dec 2022. c19early.org/il
0 0.5 1 1.5+ All studies 35% Mortality 72% Hospitalization 40% Viral clearance 58% RCTs 35% Early 35% Favorspeg.. lambda Favorscontrol
Peginterferon Lambda COVID-19 studies. Submit updates/corrections.
Dec 2
Covid Analysis (Preprint) (meta analysis) Peginterferon Lambda for COVID-19: real-time meta analysis of 3 studies
Statistically significant improvement is seen for hospitalization. 2 studies from 2 independent teams in 2 different countries show statistically significant improvements in isolation (not for the most serious outcome). • Meta analysis ..
Mar 17
Eiger BioPharmaceuticals (Preprint) Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study
72% lower mortality [p=0.38], 43% lower hospitalization [p=0.04], and 51% fewer combined hospitalization/ER visits [p=0.002]. High-risk outpatient RCT with 916 peginterferon lambda patients and 1,020 control patients, showing significantly lower hospitalization/ER visits with treatment. Single subcutaneous injection. For more discussion see [twitter.com].
Mar 30
2021
Jagannathan et al., Nature Communications, doi:10.1038/s41467-021-22177-1 Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
no change in hospitalization [p=1], 6% worse recovery [p=0.76], and 14% worse viral clearance [p=0.91]. RCT 120 outpatients with mild/moderate COVID-19, showing no significant differences with peginterferon lambda-1a treatment. 180μg subcutaneous peginterferon lambda-1a. NCT04331899.
Nov 12
2020
Feld et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30566-X (date from earlier preprint) Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
75% lower progression [p=0.35] and 66% improved viral clearance [p=0.03]. Small outpatient RCT with 30 peginterferon lambda and 30 control patients, showing improved viral clearance with treatment. Single subcutaneous injection of peginterferon lambda 180μg. NCT04354259.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit